1. Atopic Dermatitis Treatment Landscape

3. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Incidence of Atopic Dermatitis

5. Location, Location, Location

6. Assessing the Severity of AD Comparing EASI, SCORAD, and IGA

7. Patient-Reported Burden of AD

8. Impact of AD on Quality of Life

9. Impact of AD on Mental Health

10. Burden of AD

11. Novel Treatments for AD

12. CHRONOS: Dupilumab for the Management of Moderate-to-Severe AD

13. CHRONOS: Dupilumab Efficacy

14. Dupilumab Increased Incidence of Conjunctivitis

15. Lebrikizumab

16. Lebrikizumab Efficacy: Results From TREBLE

17. Tralokinumab Efficacy

18. Nemolizumab: IL-31R Targeting Antibody

19. Nemolizumab Efficacy

20. JAK Inhibitors

21. Novel Topical Agents: Crisaborole

22. Topical JAK Inhibitors

23. Other Agents in Development for AD

24. Is the Patient a Candidate for Systemic Treatment

25. Take-Home Messages